Table 4.
Relationships between the BRAFV600E mutation and clinicopathologic characteristics of 943 patients with PTC
| Variable | The overall PTC | PTC > 10 mm group | PTMC | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive | Negative | Uni- and multivariate analysis | Positive | Negative | Uni- and multivariate analysis | Positive | Negative | Uni- and multivariate analysis | |||||||
| n(%) | n(%) | P | P | OR(95CI) | n(%) | n(%) | P | P | OR(95CI) | n(%) | n(%) | P | P | OR(95CI) | |
| Gender | |||||||||||||||
| Male | 199(85) | 34(15) | 0.974 | 86(80) | 21(20) | 0.324 | 113(90) | 13(10) | 0.287 | ||||||
| Female | 607(86) | 103(14) | 225(85) | 41(15) | 382(86) | 62(14) | |||||||||
| Age (years) * | 46.3 ± 11.8 | 44.0 ± 11.9 | 0.03 | < 0.001 | 1.04 (1.02–1.06) | 46.3 ± 11.7 | 41.0 ± 3.1 | 0.002 | 0.004 | 1.04 (1.01–1.06) | 46.2 ± 10.9 | 46.6 ± 10.1 | 0.804 | ||
| Tumor diameter (mm) * | 1.1 ± 0.9 | 1.3 ± 1.2 | 0.04 | 0.283 | 1.9 ± 0.9 | 2.3 ± 1.2 | 0.04 | 0.756 | 0.6 ± 0.2 | 0.5 ± 0.2 | < 0.001 | < 0.001 |
8.19 (2.73–24.57) |
||
| Focality | |||||||||||||||
| Uni | 579(84) | 109(16) | 0.06 | 209(81) | 50(19) | 0.039 | 0.057 | 370(86) | 59(14) | 0.464 | |||||
| Multi | 227(89) | 28(11) | 102(90) | 12(11) | 125(89) | 16(11) | |||||||||
| HT | |||||||||||||||
| No | 771(86) | 122(14) | 0.002 | 0.005 | 0.35 (0.17–0.73) | 301(84) | 57(16) | 0.087 | 470(88) | 65(12) | 0.007 | 0.03 |
0.42 (0.19–0.92) |
||
| Yes | 35(70) | 15(30) | 10(67) | 5(33) | 25(71) | 10(29) | |||||||||
| CLNM | |||||||||||||||
| No | 379(86) | 61(14) | 0.588 | 87(89) | 11(10) | 0.095 | 292(85) | 50(15) | 0.206 | ||||||
| Yes | 427(85) | 76(15) | 224(81) | 51(19) | 203(89) | 25(11) | |||||||||
| T stage | |||||||||||||||
| T1 | 724(86) | 114(14) | 0.02 | 0.683 | 229(85) | 39(15) | 0.088 | 495(87) | 75(13) | – | |||||
| T2 + T3 | 82(78) | 23(22) | 82(78) | 23(22) | – | – | |||||||||
| Tumor stage | |||||||||||||||
| I | 728(85) | 128(15) | 0.248 | 262(82) | 58(18) | 0.065 | 466(87) | 70(13) | 0.783 | ||||||
| II | 78(90) | 9(10) | 49(93) | 4(8) | 29(85) | 5(15) | |||||||||
Abbreviations: PTC papillary thyroid carcinoma, PTMC papillary thyroid microcarcinoma, HT Hashimoto’s thyroiditis, CLNM central lymph node metastasis
*Numbers are presented as means ± standard deviation